Jazz Pharmaceuticals plc financials

JAZZ CIK 0001232524

Source: EDGAR filings · Built 2026-06-02T03:20:53Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 1.30B 1.36B 1.07B 1.24B 750.54M 884.64M
EBITDA -388.64M 749.43M 608.98M -35.23M 196.98M 396.77M
Working Capital 1.92B 3.59B 1.90B 1.67B 1.80B 2.19B
Net Debt 4.04B 3.75B 4.29B 4.94B 5.57B 1.19B
Gross Margin 25.86%
Operating Margin -10.08% 17.61% 15.09% -1.79% 5.50% 16.00%
Net Margin -8.35% 13.77% 10.82% -6.12% -10.65% 10.10%
Return on Equity (ROE) -8.25% 13.68% 11.10% -7.26% -8.31% 6.52%
Return on Assets (ROA) -3.05% 4.66% 3.64% -2.07% -2.68% 3.65%
Current Ratio 1.86× 4.46× 2.24× 2.79× 3.23× 4.34×
Debt-to-Equity 1.26× 1.51× 1.55× 1.89× 1.55× 0.61×
Effective Tax Rate 43.39% -19.44% -40.25% 42.56% -191.53% 12.18%
Cash Conversion Ratio -3.81× 2.49× 2.63× -5.68× -2.36× 3.77×
Accruals Ratio -0.15× -0.07× -0.06× -0.14× -0.09× -0.10×
SBC % of Revenue 6.82% 6.10% 5.92% 6.07% 6.11% 5.12%
CapEx Coverage 22.93× 36.25× 44.87× 43.15× 27.84× 59.96×
Free Cash Flow Per Share $21.26 $20.56 $14.82 $19.87 $12.57 $15.65

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 14.24× 20.16× 39.11×
P/FCF 8.00× 5.99× 8.30× 8.02× 10.13× 10.54×
FCF Yield 12.51% 16.70% 12.04% 12.47% 9.87% 9.48%
EV / EBITDA 14.97× 19.62× 68.13× 26.37×
P/S 2.45× 1.83× 2.00× 2.75× 2.54× 3.92×
P/B 2.42× 1.82× 2.05× 3.26× 1.98× 2.53×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 4.27B 4.07B 3.83B 3.66B 3.09B 2.36B
Gross Profit 611.15M
Selling, General and Administrative Expense 1.81B 1.39B 1.34B 1.42B 1.45B 854.23M
Operating Income (Loss) -430.24M 716.63M 578.58M -65.53M 170.28M 378.07M
Income Tax Expense (Benefit) -272.44M -91.43M -119.91M -158.65M 216.12M 33.52M
Net Income (Loss) Attributable to Parent -356.15M 560.12M 414.83M -224.06M -329.67M 238.62M
Earnings Per Share, Basic $-5.84 $9.06 $6.55 $-3.58 $-5.52 $4.28
Weighted Average Number of Shares Outstanding, Basic 60.98M 61.84M 63.29M 62.54M 59.69M 55.71M
Earnings Per Share, Diluted $-5.84 $8.65 $6.10 $-3.58 $-5.52 $4.22
Weighted Average Number of Shares Outstanding, Diluted 60.98M 66.01M 72.07M 62.54M 59.69M 56.52M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 1.39B 2.41B 1.51B 881.48M 591.45M 1.06B
Assets, Current 4.17B 4.63B 3.44B 2.61B 2.61B 2.84B
Assets 11.66B 12.01B 11.39B 10.84B 12.30B 6.54B
Long-term Debt 5.36B 6.11B 5.71B 5.72B 6.05B 2.09B
Liabilities, Current 2.24B 1.04B 1.54B 933.19M 809.30M 653.75M
Long-term Debt, Excluding Current Maturities 4.33B 6.08B 5.11B 5.69B 6.02B 1.85B
Stockholders' Equity Attributable to Parent 4.32B 4.09B 3.74B 3.09B 3.97B 3.66B
Common Stock, Shares, Outstanding 61.44M 60.63M 62.26M 63.21M 61.63M 56.17M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 1.36B 1.40B 1.09B 1.27B 778.51M 899.65M
Payments to Acquire Property, Plant, and Equipment 58.75M 38.07M 23.96M 29.05M 27.64M 15.00M
Net Cash Provided by (Used in) Investing Activities -1.51B -508.19M -163.06M -446.23M -5.21B -1.01B
Payments for Repurchase of Common Stock 125.02M 311.43M 269.76M 54.00K 0 146.54M
Net Cash Provided by (Used in) Financing Activities -873.38M 20.52M -305.25M -529.49M 3.97B 528.07M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (JAZZ CIK 0001232524), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

DC

Dakota Gold Corp.

MSA

MSA Safety Inc

USB

US BANCORP \DE\